SCHEMBL2201169

SCHEMBL2201169

CC(C)N1CCC(Cc2ccc(N)cc2C(F)(F)F)CC1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.49
HRH3 Q9Y5N1 6/20 0.39
GLA P06280 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37
KCNH2 Q12809 1/20 0.36
DDR1 Q08345 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
SLC2A1 P11166 1/20 0.33
P2RX7 Q99572 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTR2B P41595 1/20 0.32
MAPK14 Q16539 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12426573 0.86 HRH3 (0.39) NR1H2HRH3GAAKCNH2DDR1
SCHEMBL272847 0.85 NR1H2 (0.63) NR1H2HRH3GLAPOLBGAA
SCHEMBL2201709 0.83 NR1H2 (0.53) NR1H2HRH3GLAPOLBGAA
SCHEMBL24192958 0.80 TDP1 (0.42) HRH3KCNH2CYP2C9CYP2C19
SCHEMBL1408506 0.79 NR1H2 (0.73) NR1H2GLAPOLBGAATSHR
SCHEMBL29958917 0.79 NR1H2 (0.73) NR1H2GLAPOLBGAATSHR
SCHEMBL24192359 0.79 TP53 (0.37) HRH3KCNH2DDR1L3MBTL1P2RX7
SCHEMBL24192437 0.79 NR1H2 (0.51) NR1H2GLAPOLBGAATSHR
SCHEMBL24192440 0.78 NR1H2 (0.51) NR1H2DDR1SLC6A4
SCHEMBL24192748 0.76 EPHX2 (0.54) NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022008383-A1 ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2022-01-13 WO disclosed
US-7977338-B2 Phenylacetamides being FLT3 inhibitors NOVARTIS AG (CH) 2011-07-12 US disclosed
US-20100075980-A1 Phenylacetamides being FLT3 Inhibitors NOVARTIS AG (CH) 2010-03-25 US disclosed
CN-101558068-A Phenylacetamides useful as protein kinase inhibitors NOVARTIS AG (CH) 2009-10-14 CN disclosed
EP-2074125-A1 PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS Novartis Ag (CH) 2009-07-01 EP disclosed
WO-2008046802-A1 PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075980-A1 Phenylacetamides being FLT3 Inhibitors FLT3, JAK2, ABL1 NR1H2 2592/4885HRH3 1136/4885GLA 3484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.